Intrust Bank’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.73M Buy
11,348
+438
+4% +$67.1K 0.14% 119
2025
Q4
$1.5M Buy
10,910
+351
+3% +$46K 0.12% 121
2025
Q3
$1.35M Sell
10,559
-8
-0.1% -$976 0.11% 129
2025
Q2
$1.28M Sell
10,567
-70
-0.7% -$7.89K 0.11% 135
2025
Q1
$1.19M Sell
10,637
-276
-3% -$29.4K 0.12% 138
2024
Q4
$1.06M Buy
10,913
+265
+2% +$28.3K 0.11% 144
2024
Q3
$1.22M Buy
10,648
+161
+2% +$18.3K 0.12% 133
2024
Q2
$1.12M Sell
10,487
-1,177
-10% -$118K 0.12% 133
2024
Q1
$1.13M Sell
11,664
-719
-6% -$73.7K 0.12% 142
2023
Q4
$1.25M Buy
12,383
+1,202
+11% +$116K 0.15% 127
2023
Q3
$1.14M Buy
11,181
+341
+3% +$34.6K 0.15% 125
2023
Q2
$1.09M Buy
10,840
+321
+3% +$32.1K 0.13% 137
2023
Q1
$968K Buy
10,519
+1,170
+13% +$102K 0.12% 147
2022
Q4
$848K Buy
9,349
+1,677
+22% +$141K 0.12% 149
2022
Q3
$584K Sell
7,672
-281
-4% -$23.3K 0.09% 195
2022
Q2
$672K Buy
7,953
+1,303
+20% +$114K 0.1% 186
2022
Q1
$584K Buy
6,650
+1,773
+36% +$154K 0.07% 223
2021
Q4
$427K Sell
4,877
-474
-9% -$39.4K 0.05% 262
2021
Q3
$438K Sell
5,351
-831
-13% -$74.8K 0.06% 248
2021
Q2
$564K Buy
6,182
+1,017
+20% +$90.6K 0.08% 212
2021
Q1
$442K Buy
5,165
+387
+8% +$34.7K 0.06% 237
2020
Q4
$451K Buy
+4,778
New +$418K 0.07% 222
2020
Q1
Sell
-2,429
Closed -$230K 341
2019
Q4
$230K Buy
2,429
+28
+1% +$2.51K 0.05% 311
2019
Q3
$209K Sell
2,401
-26
-1% -$2.33K 0.05% 327
2019
Q2
$222K Sell
2,427
-773
-24% -$65.4K 0.05% 330
2019
Q1
$276K Buy
3,200
+25
+0.8% +$2.01K 0.07% 310
2018
Q4
$244K Sell
3,175
-65
-2% -$5.06K 0.07% 311
2018
Q3
$250K Sell
3,240
-346
-10% -$25.6K 0.06% 334
2018
Q2
$243K Sell
3,586
-699
-16% -$48.2K 0.07% 317
2018
Q1
$311K Sell
4,285
-744
-15% -$56.6K 0.09% 276
2017
Q4
$378K Sell
5,029
-305
-6% -$23K 0.11% 253
2017
Q3
$410K Sell
5,334
-48
-0.9% -$3.63K 0.13% 224
2017
Q2
$403K Sell
5,382
-1,116
-17% -$79.1K 0.14% 217
2017
Q1
$433K Sell
6,498
-1,748
-21% -$116K 0.15% 204
2016
Q4
$538K Sell
8,246
-3,374
-29% -$219K 0.2% 151
2016
Q3
$822K Buy
11,620
+21
+0.2% +$1.53K 0.33% 91
2016
Q2
$857K Buy
11,599
+148
+1% +$10.2K 0.35% 87
2016
Q1
$744K Buy
11,451
+2,176
+23% +$148K 0.27% 124
2015
Q4
$715K Sell
9,275
-278
-3% -$22.1K 0.27% 121
2015
Q3
$787K Sell
9,553
-104
-1% -$9.26K 0.3% 104
2015
Q2
$851K Buy
9,657
+197
+2% +$18.1K 0.3% 106
2015
Q1
$836K Buy
9,460
+1,331
+16% +$118K 0.29% 107
2014
Q4
$675K Sell
8,129
-336
-4% -$27.9K 0.25% 120
2014
Q3
$714K Buy
8,465
+106
+1% +$8.58K 0.28% 113
2014
Q2
$678K Buy
8,359
+460
+6% +$36.2K 0.25% 115
2014
Q1
$602K Buy
7,899
+920
+13% +$67K 0.25% 124
2013
Q4
$503K Buy
6,979
+82
+1% +$5.7K 0.22% 145
2013
Q3
$474K Buy
6,897
+120
+2% +$7.94K 0.23% 146
2013
Q2
$429K Buy
+6,777
New +$441K 0.19% 177

Other funds holding NVS

Intrust Bank's NVS Position: Q1 2026 in Review

Intrust Bank increased its Novartis (NVS) stake by 4% in Q1 2026, buying an estimated $67.1K and bringing the position to 11,348 shares worth $1.73M. The position accounts for 0.14% of the portfolio, ranked #119.

Intrust Bank first reported a position in NVS in Q2 2013 and has held it in 49 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Intrust Bank held 11,348 shares of Novartis worth $1.73M as of Q1 2026.
  • Intrust Bank bought 438 Novartis shares in Q1 2026, an estimated $67.1K.
  • Novartis made up 0.14% of Intrust Bank's portfolio in Q1 2026, its #119 holding.
  • Intrust Bank first reported a position in Novartis in Q2 2013 and has held it in 49 quarters since.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Intrust Bank's 13F filing for Q1 2026, filed 6 May 2026.